Loading…
← CockpitCompetitor Analysis › 4123.TWO Center Laboratories, Inc.Open in the cockpit ↗

Center Laboratories, Inc.4123.TWOCompetitor analysis, valuation and peers

Taiwan · TWD·Health Care›Pharmaceuticals: Major
Momentum weak 26
Mkt cap
$639M
US dollars, full cap
Free float
78%
of shares outstanding
$/day
$962,998
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-4.3 pp
WACC 5.0%
Hurdle
+20 pp
Req g minus delivered
Close · TWDNT$27.10
1D-2.2%
1W-4.6%
1M-12.6%
3M-30.5%
6M-29.3%
YTD-34.9%
1Y-20.4%
ATR %2.7%
52w lowhigh47.3% off high

What Center Laboratories does

No business profile yet.

Center Laboratories at a glance

Size Center Laboratories (4123.TWO) is a Taiwan Health Care company (Pharmaceuticals: Major) with a market value of $639M, the 354th largest of 648 Taiwan companies the cockpit tracks. Shares closed at NT$27.10 on 18 Nov 2026.

Performance Over six months the shares fell 29.3%, against -18.1% for the median peer and -3.4% for the Taiwan market (cap-weighted) — 7th lowest of 20 in its peer set.

Growth Revenue grew 13.6% over the last twelve months (peer median +8.6%); the operating margin is 9.2% (peer median 7.9%).

Valuation It trades at 12.8× enterprise value to sales against a peer median of 3.2× (3rd most expensive of 17).

Price implies For today's price to make sense, revenue must grow about 36% a year for seven years (Req g). Recent delivered growth is +16%, so the hurdle is +20 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 4.3 points below its cost of capital (5.0% WACC).

Relative performance

8010021 May 202621 Aug 202618 Nov 2026Peer median 824123.TWO 71
Six months, rebased to 100: Center Laboratories against the median of its 20 peers (local-currency closes).

Center Laboratories financials

Reported figures in TWD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueNT$1.78BNT$1.52BNT$1.62BNT$1.39BNT$768M
Revenue growth—-6%+16%+82%—
Gross profitNT$726MNT$552MNT$678MNT$618MNT$393M
EBITDANT$346MNT$257MNT$391MNT$221MNT$99.6M
Net income-NT$1.69BNT$9.32B-NT$1.10B-NT$995MNT$102M
Free cash flowNT$289M-NT$21.1MNT$317M-NT$774MNT$226M
Capital expenditureNT$147MNT$208MNT$178MNT$172MNT$8.43M
Total debtNT$4.16BNT$4.70BNT$6.53BNT$5.62BNT$3.47B

Quarterly statements and history in the cockpit →

Center Laboratories competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-60%-40%-20%0%+20%-40%-20%0%300016000566INNOVACAP300878ABUSFDCBCAX301211OLMASPARC4105ORCHPHARMA002940603567002793ANNX6884884123.TWO6-month return →1-month return →
Up and to the right = strong over both horizons. Center Laboratories is the large dot.

Fundamentals: revenue growth against valuation

0%+1,000%+2,000%+3,000%0×10×20×300016000566INNOVACAP300878ABUS301211SPARCORCHPHARMA3001946035671857506884884123.TWORevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Center Laboratories is the large dot.

Capital: growth delivered against growth the price implies

-20%0%+20%-20%0%20%300016INNOVACAPFDC41053001940029406035670027931857506884884123.TWOGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Center Laboratories is the large dot.

Center Laboratories competitors and peer comparison

How Center Laboratories compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Center Laboratories against its 20 peers (data as of 18 Nov 2026)
Measure4123.TWOPeer medianRank in peer set
1-month return-12.6%-9.1%5th lowest of 20
6-month return-29.3%-18.1%7th lowest of 20
Distance from 52-week high-47.3%-36.4%8th lowest of 20
Revenue growth (TTM)+13.6%+8.6%6th highest of 17
Operating margin9.2%7.9%8th highest of 16
EV / Sales12.8×3.2×3rd most expensive of 17
Growth the price implies (Req g, 7 yrs)36.3%9.6%most demanding of 11
Growth delivered (Del g)+16.2%+6.6%3rd highest of 11
Hurdle (Req g minus delivered)+20.1 pp+10.1 pp2nd most demanding of 11
ROIC minus cost of capital-4.3 pp-3.4 pp6th lowest of 14
EV / EBITDA66.0×8.2×most expensive of 7
Net debt / EBITDA5.2×-0.4×2nd most indebted of 8

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Center Laboratories 4123.TWOTaiwan$639M-29%+14%9%12.8×36.3%+16.2%
Beijing Beilu Pharmaceutical 300016.SZChina$641M-19%+23%11%3.0×9.1%+7.9%
Hainan Haiyao 000566.SZChina$642M-18%-18%-50%10.6×n/an/a
Innova Captab INNOVACAP.NSIndia$645M+20%+37%12%3.4×27.1%+31.4%
Zhejiang Wecome Pharmaceutical 300878.SZChina$632M-18%+92%-41%16.9×n/an/a
Arbutus Biopharma ABUSUnited States$630M-6%+1,143%80%1.6×n/an/a
FDC FDC.NSIndia$653M+3%+10%14%2.4×25.2%+10.3%
Bicara Therapeutics BCAXUnited States$623M-54%n/an/an/an/an/a
Hubei Biocause Heilen Pharmaceutical 301211.SZChina$619M-10%+13%4%5.3×n/an/a
Olema Pharmaceuticals OLMAUnited States$619M-49%n/an/an/an/an/a
Sun Pharma Advanced Research SPARC.NSIndia$660M+6%+3,141%84%2.5×n/an/a
TTY Biopharm 4105.TWOTaiwan$615M+10%+5%29%3.0×-8.7%+8.8%
Orchid Pharma ORCHPHARMA.NSIndia$613M+30%+11%0%6.1×n/an/a
Fuan Pharmaceutical (Group) 300194.SZChina$612M-14%-3%-1%2.4×10.9%-5.9%
Zhejiang Anglikang Pharmaceutical 002940.SZChina$612M-52%-13%10%3.3×10.1%+2.1%
HeiLongJiang ZBD Pharmaceutical 603567.SSChina$610M-39%-82%n/a25.1×9.1%-25.1%
Achieve Life Sciences QUITUnited States$609Mn/an/an/an/an/an/a
Luoxin Pharmaceuticals Group Stock 002793.SZChina$609M-26%-10%-9%2.0×-1.0%-17.9%
Chongkundang 185750.KSSouth Korea$609M-27%+6%4%0.5×-6.6%+5.4%
Annexon ANNXUnited States$671M-30%n/an/an/an/an/a
Jiangsu Aidea Pharmaceutical 688488.SSChina$672M-35%+7%8%6.7×31.9%+19.8%

Questions

Which companies are Center Laboratories's closest peers?
The cockpit's peer set: Beijing Beilu Pharmaceutical (300016.SZ), Hainan Haiyao (000566.SZ), Innova Captab (INNOVACAP.NS), Zhejiang Wecome Pharmaceutical (300878.SZ), Arbutus Biopharma (ABUS), FDC (FDC.NS), Bicara Therapeutics (BCAX), Hubei Biocause Heilen Pharmaceutical (301211.SZ).
Is Center Laboratories expensive compared with its peers?
On ev / sales it trades at 12.8× against a peer median of 3.2×, 3rd most expensive of 17 in its peer set. For today's price to make sense, revenue must grow about 36% a year for seven years (Req g). Recent delivered growth is +16%, so the hurdle is +20 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Center Laboratories stock performed?
Over six months to 18 Nov 2026 the shares returned -29.3% against -18.1% for the median peer; over one year -20.4%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.